Is Cabotegravir approved in China?

Cabotegravir (Cabotegravir) has not been approved for marketing in China. However, drug approval and marketing status may continue to change, so it is recommended that you check the latest information released by the Chinese drug regulatory agency or consult your local pharmaceutical agency to learn about the latest approval status of cabotegravir in China.

In China, drugs need to go through the approval process of the National Medical Products Administration (National Medical Products Administration,NMPA) to ensure the safety, effectiveness and quality of the drugs. After approval, the drug can be legally marketed and sold in China for patient use.

If you or someone you know needs to use cabotegravir or other antiretroviral drugs, it is recommended to consult a professional doctor or medical provider for appropriate treatment recommendations and options. Prompt treatment is important to manageHIVinfection and improve patient quality of life.

Cabotegravir is often given as part of combination antiretroviral therapy (cART). Combination therapy uses two or more antiretroviral drugs of different classes at the same time to slow down the replication of HIV viruses, reduce viral load, improve immune function, and delay the progression of HIV disease. Combination therapy can effectively control viral replication and reduce the amount of virus in the body, thereby maintaining the patient's immune function, slowing down the progression of HIV disease, and improving the patient's quality of life.

Cabotegravir is not currently on the market in China, so patients cannot purchase it domestically and need to purchase cabotegravir through overseas channels. Foreign cabotegravir only has original drugs, mainly European original drugs, and the price is very high, about 16,000 yuan.